In summary, we reported that RvD3 significantly alleviated psoriasiform itch and skin inflammation in the IMQ-animal model of psoriasis via activation of the ALX/FPR2 receptor, inhibition of TRPV1 activity, and reduction in CGRP release. The gene discussed is TRPV1; the disease is psoriasis.